Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Non-Current Deffered Revenue (2016 - 2022)

Cytokinetics (CYTK) has disclosed Non-Current Deffered Revenue for 10 consecutive years, with $87.0 million as the latest value for Q3 2022.

  • Quarterly Non-Current Deffered Revenue changed 0.0% to $87.0 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $87.0 million through Sep 2022, changed 0.0% year-over-year, with the annual reading at $87.0 million for FY2021, 0.0% changed from the prior year.
  • Non-Current Deffered Revenue for Q3 2022 was $87.0 million at Cytokinetics, roughly flat from $87.0 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $87.0 million in Q4 2020, with the low at $87.0 million in Q4 2020.
  • Average Non-Current Deffered Revenue over 3 years is $87.0 million, with a median of $87.0 million recorded in 2020.
  • Peak annual rise in Non-Current Deffered Revenue hit 0.0% in 2021, while the deepest fall reached 0.0% in 2021.
  • Over 3 years, Non-Current Deffered Revenue stood at $87.0 million in 2020, then changed by 0.0% to $87.0 million in 2021, then changed by 0.0% to $87.0 million in 2022.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $87.0 million, $87.0 million, and $87.0 million for Q3 2022, Q1 2022, and Q4 2021 respectively.